Safety and Efficacy of SARS-CoV-2–Specific T-Cell Therapy for Severe COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
Nat. Med. 2023 Jul 17;[EPub Ahead of Print], A Papadopoulou, G Karavalakis, E Papadopoulou, A Xochelli, Z Bousiou, A Vogiatzoglou, PG Papayanni, A Georgakopoulou, M Giannaki, F Stavridou, I Vallianou, M Kammenou, E Varsamoudi, V Papadimitriou, C Giannaki, M Sileli, Z Stergiouda, G Stefanou, G Kourlaba, G Gounelas, M Triantafyllidou, E Siotou, A Karaglani, E Zotou, G Chatzika, A Boukla, A Papalexandri, MG Koutra, D Apostolou, G Pitsiou, P Morfesis, M Doumas, T Karampatakis, N Kapravelos, M Bitzani, M Theodorakopoulou, E Serasli, G Georgolopoulos, I Sakellari, A Fylaktou, S Tryfon, A Anagnostopoulos, E YannakiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.